Exploring Issues in Difficult-to-Treat Hypertension

Journal of Clinical Hypertension

Volumn 15, Issue 12, 2013, Pages 859-864

  Weber, Michael A ^a  

^a Downstate Health Sciences University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; AZILSARTAN MEDOXOMIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; SPIRONOLACTONE; TELMISARTAN;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTERY DISEASE; AWARENESS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; EDUCATION PROGRAM; FOLLOW UP; HEALTH CARE PLANNING; HEALTH EDUCATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FAILURE; KIDNEY NERVE; NEPHROLOGY; OBESITY; PATIENT COMPLIANCE; POLYPHARMACY; POTASSIUM BLOOD LEVEL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RENAL ARTERY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; SLEEP DISORDER; TREATMENT DURATION; TREATMENT REFUSAL;

ANTIHYPERTENSIVE AGENTS; DRUG RESISTANCE; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 84888866532     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12219     Document Type: Editorial

References (48)

1. Sarafidis PA. Epidemiology of resistant hypertension. J Clin Hypertens (Greenwich). 2011;13:523-528.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
3. Kaplan NM. Resistant hypertension. J Hypertens. 2005;23:1441-1444.
4. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52:1749-1757.
5. Weber MA, Julius S, Kjeldsen SE, et al. Cardiovascular outcomes in hypertensive patients: comparing single agent therapy with combination therapy. J Hypertens. 2012;30:2213-2222.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs. diuretics: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart A Trial (ALLHAT). JAMA. 2002;288:2981-2997.
7. Krousel-Wood M, Muntner P, Carson A, et al. Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC7 guidelines. J Clin Hypertens (Greenwich). 2012;14:277-283.
8. Shafi S, Sarac E, Tran H. Ambulatory blood pressure monitoring in patients with chronic kidney disease and resistant hypertension. J Clin Hypertens (Greenwich). 2012;14:611-617.
9. Agarwal R. Home and ambulatory blood pressure monitoring in chronic kidney disease. Curr Opin Nephrol Hypertens. 2009;18:507-512.
10. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8, 295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.
11. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050.
12. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825-834.
13. Huebschmann AG, Mizrahi T, Soenksen A, et al. Reducing clinical inertia in hypertension treatment: a pragmatic randomized controlled trial. J Clin Hypertens (Greenwich). 2012;14:322-329.
14. Nelson SAE, Dresser GK, Vendervoort MK, et al. Barriers to blood pressure control: a STITCH substudy. J Clin Hypertens (Greenwich). 2011;13:73-80.
15. Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy intensification and medication non-adherence for blood pressure control in patients with coronary disease. Arch Intern Med. 2008;168:271-276.
16. Irvin MR, Shimbo D, Mann DM, et al. Prevalence and correlates of low medication adherence in apparent treatment resistant hypertension. J Clin Hypertens (Greenwich). 2012;14:694-700.
17. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23:2093-2100.
18. Trogdon JG, Larsen B, Larsen D, et al. Cost effectiveness evaluation of a collaborative patient education hypertension intervention in Utah. J Clin Hypertens (Greenwich). 2012;14:760-766.
19. Handler J. Malingering: an unusual cause of resistant hypertension. J Clin Hypertens (Greenwich). 2012;14:475-478.
20. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics. National Health and Nutrition Examination Survey Data. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005-2008. http://www.cdc.gov/nchs/nhanes.htm (Accessed 2010).
21. Bansil P, Kuklina EV, Merritt RK, Yoon PW. Associations between sleep disorders, sleep duration, quality of sleep, and hypertension: results from the National Health and Nutrition Examination Survey, 2005-2008. J Clin Hypertens (Greenwich). 2011;13:739-743.
22. Walia H, Strohl K, Koo B, et al. Are sleep symptoms predictors of resistant hypertension in a population based sample? Findings from the National Health and Nutrition Examination Survey. J Clin Hypertens (Greenwich). 2012;14:530-536.
23. Garcia EA, Lopez JR, Meier JL, et al. Resistant hypertension and undiagnosed primary hyperaldosteronism detected by use of a computerized database. J Clin Hypertens (Greenwich). 2011;13:487-491.
24. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
25. Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14:7-12.
26. Mann SJ. Drug therapy for resistant hypertension: a simplified, mechanistic approach. J Clin Hypertens (Greenwich). 2011;13:120-130.
27. Jamerson K, Weber MA, Bakris GL, et al. Benazapril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Engl J Med. 2008;359:2417-2428.
28. Mann SJ, Parikh NS. A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. J Clin Hypertens (Greenwich). 2012;14:191-197.
29. Neutel JM, Mancia G, Black HR, et al. Single pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich). 2012;14:206-215.
30. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255-64.
31. Sica D, Bakris GL, White WB, et al. Blood pressure lowering efficacy of the fixed dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012;14:284-292.
32. Sica DA. Chlorthalidone - has it always been the best thiazide-type diuretic? Hypertension. 2006;47:321-322.
33. Eguchi K, Satoshi H, Ishikawa S, et al. Aggressive blood pressure lowering therapy guided by home blood pressure monitoring improves target organ damage in hypertensive patients with type 2 diabetes/pre-diabetes. J Clin Hypertens (Greenwich). 2012;14:422-428.
34. ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
35. Izzo JL, Chrysant SG, Kereiakes DJ, et al. 24 hour efficacy and safety of triple combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY Ambulatory Blood Pressure Substudy. J Clin Hypertens (Greenwich). 2011;13:873-880.
36. Kereiakes DJ, Chrysant SG, Izzo JL, et al. Long term efficacy and safety of triple combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich). 2012;14:149-157.
37. Wright RF, Duprez D, Purkayastha D, et al. Combination angiotensin receptor blocker/calcium channel blocker with HCTZ vs. the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the Exforge as Compared to Losartan Treatment in stage 2 systolic hypertension (EXALT) study. J Clin Hypertens (Greenwich). 2011;13:588-597.
38. Murray AV, Koenig W, Garcia-Puig J, et al. Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54 week, open label study. J Clin Hypertens (Greenwich). 2012;14:821-827.
39. Sherrill B, Halpern M, Khan S, et al. Single pill vs. free equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898-909.
40. Muszbek N, Brixner D, Benedict A, et al. The economic consequences of non-compliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008;62:338-351.
41. Cohen DL, Townsend RR. Renal denervation revisited: promising treatment for resistant hypertension? J Clin Hypertens (Greenwich). 2011;13:931-932.
42. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903-1909.
43. Ott C, Schmid A, Ditting T, et al. Renal denervation in a hypertensive patient with end stage renal disease and small arteries: a direction for future research. J Clin Hypertens (Greenwich). 2012;14:799-801.
44. Campese VM, Kogosove E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25:878-882.
45. Himmel F, Bode F, Mortensen K, et al. Successful single-sided renal denervation approach in a patient with stenosis of an accessory renal artery. J Clin Hypertens (Greenwich). 2012;14:187-188.
46. Ho HH, Foo D, Ong PJL. Successful pre-operative treatment of a patient with resistant hypertension who had percutaneous renal denervation therapy before bariatric surgery. J Clin Hypertens (Greenwich). 2012;14:569-570.
47. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197-203.
48. Mortensen K, Franzen K, Himmel F, et al. Catheter based renal sympathetic denervation improves central hemodynamics and arterial stiffness: a pilot study. J Clin Hypertens (Greenwich). 2012;14:861-870.